| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17240 R72142 |
Albertini, 2023 | Intrauterine growth restriction (birth weight <10th percentile based on the World Health Organization growth curves for female and male infants) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 2.41 [0.10;57.74] C | 2/16 0/7 | 2 | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13913 R54438 |
Duan, 2018 | Small for gestational age (birth weight <10th percentile for the corresponding gestational week) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 1.50 [0.90;2.30] | 35/324 32,488/374,391 | 32,523 | 324 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14073 R55407 |
Tanaka, 2016 | Fetal growth restriction (considered equivalent to light for gestational age, birth weight <10th percentile for gestational age) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 6.35 [0.95;43.30] | 2/12 3/100 | 5 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.74 [0.96;3.14] | 32,530 | 352 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded